Dexcom Inc (DXCM) concluded trading on Wednesday at a closing price of $66.86, with 4.52 million shares of worth about $302.3 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -7.63% during that period and on April 23, 2025 the price saw a gain of about 0.80%. Currently the company’s common shares owned by public are about 390.70M shares, out of which, 386.62M shares are available for trading.
Stock saw a price change of -3.42% in past 5 days and over the past one month there was a price change of -11.23%. Year-to-date (YTD), DXCM shares are showing a performance of -14.03% which decreased to -48.85% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $57.52 but also hit the highest price of $139.24 during that period. The average intraday trading volume for Dexcom Inc shares is 4.22 million. The stock is currently trading 0.50% above its 20-day simple moving average (SMA20), while that difference is down -10.84% for SMA50 and it goes to -13.69% lower than SMA200.
Dexcom Inc (NASDAQ: DXCM) currently have 390.70M outstanding shares and institutions hold larger chunk of about 92.64% of that.
The stock has a current market capitalization of $26.22B and its 3Y-monthly beta is at 1.41. PE ratio of stock for trailing 12 months is 46.93, while it has posted earnings per share of $1.42 in the same period. Its PEG reads 2.08 and has Quick Ratio of 1.28 while making debt-to-equity ratio of 1.23. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for DXCM, volatility over the week remained 3.74% while standing at 5.03% over the month.
Stock’s fiscal year EPS is expected to rise by 23.32% while it is estimated to increase by 22.36% in next year. EPS is likely to shrink at an annualized rate of 22.57% for next 5-years, compared to annual growth of 39.06% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Mizuho on April 10, 2025 offering an Outperform rating for the stock and assigned a target price of $85 to it. Coverage by Redburn Atlantic stated Dexcom Inc (DXCM) stock as a Buy in their note to investors on February 03, 2025, suggesting a price target of $115 for the stock. On January 16, 2025, Robert W. Baird Upgrade their recommendations, while on July 26, 2024, Robert W. Baird Downgrade their ratings for the stock with a price target of $80. Stock get a Neutral rating from JP Morgan on July 26, 2024.
